New HER2-Positive Breast Cancer Therapy Launched by AstraZeneca in the Middle East
HER2-positive breast cancer therapy protocols are evolving in the region as AstraZeneca Iraq officially announces the registration and launch of a targeted treatment for advanced cases. The introduction of this medication, an antibody-drug conjugate (ADC), provides a new option for patients with advanced HER2-positive and HER2-low metastatic breast cancer who have previously faced limited management options due to standard therapy resistance.
The Context: Oncology Challenges in Iraq
Breast cancer remains the most frequently diagnosed cancer among Iraqi women, representing 34.8% of all female cancer cases. Data from 2023 indicates that Iraq recorded 8,708 new cases, with the disease ranking as the second leading cause of cancer mortality in the country. With a crude mortality rate of 7.5 per 100,000 among females, the regional need for specialized oncology solutions is urgent.
This regional development mirrors efforts seen across the Middle East, including the Saudi healthcare transformation, where governments are prioritizing the treatment of chronic diseases like cancer to improve life expectancy.
Why This Matters: The Shift to Targeted Treatment
The newly registered therapy utilizes ADC technology to specifically target cancer cells. This mechanism binds to HER2 proteins on the surface of cancer cells and releases a potent chemotherapy payload directly inside the cell. By focusing the treatment on the malignant cells, the technology aims to enhance effectiveness while minimizing damage to the surrounding healthy tissue.
“Launching this therapy in Iraq marks a significant step in our commitment to cancer care,” stated Rami Scandar, Country President for AstraZeneca Near East and Maghreb. He noted that the goal is to help physicians provide more precise and effective options for patients across the country.
Market Impact and Future Outlook
Clinical evaluations highlight that this therapy is the first HER2-directed treatment approved globally for both HER2-positive and HER2-low metastatic breast cancer. Health experts and oncologists at the Baghdad launch event emphasized that this reclassification could fundamentally change how doctors identify and treat the spectrum of HER2 expression in metastatic cases.
Dr. Tahseen Alrubaie, Secretary General of the Iraqi Cancer Board, noted that as national screening and early detection efforts grow, adding targeted therapies can support more individualized care pathways and strengthen broader cancer control strategies.
For more information on regional pharmaceutical developments, visit the AstraZeneca Official Site.
